A research success by diabetes specialist Novo Nordisk dealt a serious blow to dialysis providers’ papers on Wednesday.
Fresenius Medical Care (FMC) shares fell by almost a quarter in the morning, temporarily giving up all of their price gains for the 2023 stock market year. Most recently, the price loss was 15.86 percent to 33.37 euros.
In the USA, the shares of the US competitor DaVita on the NYSE lost 16.05 percent to 76.63 US dollars. The papers of FMC parent Fresenius also temporarily fell by 8.24 percent to 25.40 euros in Wednesday trading.
A study by Novo Nordisk with its antidiabetic drug in chronic kidney patients unexpectedly became a feared burden early on, wrote JPMorgan analyst David Adlington in his first reaction. The Danes could end the study early – because of proven effectiveness. The medium to long-term growth in the number of dialysis patients is likely to be slowed down considerably, according to the expert.
UBS expert Graham Doyle also fears this – but only in about ten years. He explains the consequences of the study with the diabetes drug for dialysis treatments: It has now been proven that the Novo drug slows the progression of chronic kidney disease (CKD). CKD is the cause of kidney failure and this in turn is the reason for dialysis treatments.
/ag/tih/stk
FRANKFURT (dpa-AFX)
Selected leverage products on DaVita HealthCare Partners
With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the lever you want and we will show you suitable open-end products on DaVita HealthCare Partners
The leverage must be between 2 and 20
Advertising